Inclusion Criteria:

- Age - 18 years and older

- Diagnosis of Polycystic Liver Disease (PLD) associated with ADPKD or isolated
Autosomal Dominant Polycystic liver Disease (ADPLD)

- Severe PLD defined as a liver volume greater than 4000 mL or symptomatic disease due
to mass effects from hepatic cysts

- Not a candidate for or declining surgical intervention

Exclusion Criteria:

- Women of childbearing potential or their sexual partners who are unwilling to employ
adequate contraception

- Creatinine greater than 3mg/dL or hemodialysis dependent

- Cancer or major systemic disease that could prevent completion of the planned
follow-up or interfere with data collection or interpretation

- Uncontrolled diabetes mellitus as defined by blood glucose levels of greater than or
equal to 250 mg/dL on 2 or more consecutive daily readings despite antidiabetic
therapy

- Neurologic/psychologic conditions preventing appropriate informed consent

- Symptomatic gallstones or biliary sludge

- Variceal bleeding or hepatic encephalopathy within prior 30 days

- Uncontrolled hypertension (Systolic blood pressure greater than 160 mmHg; Diastolic
blood pressure greater than 100 mmHg)

- Current, or prior use of somatostatin analogue (octreotide, lanreotide) in past 6
months

- History of significant adverse reaction to a somatostatin analogue